Video

Dr David Blumenthal Outlines the Result of Mergers and Acquisitions in Healthcare

David Blumenthal, MD, MPP, president of The Commonwealth Fund, discusses the role of mergers and acquisitions in delivering affordable, high-quality care.

David Blumenthal, MD, MPP, president of The Commonwealth Fund, discusses the role of mergers and acquisitions in delivering affordable, high-quality care.

Transcript

What role do you think mergers and acquisitions will play in healthcare in regard to delivering high-quality care at an affordable price?

There are some mergers and acquisitions that may be useful. I’m thinking of getting to the point where payers and providers work more closely together and one theoretical way of getting there would be to have a payer and provider merge and that has happened. Some most recently, the UnitedHealth Group and the DaVita Medical Groups have come together. I don’t see that as the future because I think it’s really hard to make those successful if they are not growing up organically as for example, Intermountain has or Geisinger has or Henry Ford over a long period of time where physicians have taken risks and grown and developed a plan that they have nurtured and believe in themselves.

I think mergers and acquisitions are an interesting new development, they show that the private sector are taking health care and it’s costs seriously and that’s great but I think they are a very difficult way to make the future better.

Related Videos
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Screenshot of Susan Wescott, RPh, MBA
Screenshot of an interview with Adam Colborn, JD
Screenshot of an interview with James Chambers, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo